Trials / Completed
CompletedNCT01001702
Oral Aripiprazole Open-Label Rollover Study
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 13 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Flexible dose between 5 mg and 30 mg Aripiprazole tablets. |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2009-10-27
- Last updated
- 2013-09-27
- Results posted
- 2013-09-27
Locations
15 sites across 6 countries: Argentina, Croatia, India, Russia, Serbia, Ukraine
Source: ClinicalTrials.gov record NCT01001702. Inclusion in this directory is not an endorsement.